FDA Approves Takeda’s Orzeyful for Narcolepsy Type 1

FDA approved Orzeyful (oveporexton), Takeda’s oral orexin receptor 2 agonist, on 5 August 2026 for narcolepsy type 1 in adults — the first medicine cleared to treat the disorder as a whole rather than its symptoms one at a time. The approval closes out a mechanism years in development: a drug that restores signaling from the very neurotransmitter system narcolepsy type 1 destroys. It also opens an unusual gap between approval and access: Orzeyful cannot be dispensed until a second federal agency finishes its own process.

What narcolepsy type 1 actually destroys

Narcolepsy type 1 is caused by the loss of orexin-producing neurons in the hypothalamus, most likely to autoimmune attack, which leaves patients with a measurable deficiency of orexin (also called hypocretin) — the neuropeptide that normally stabilizes wakefulness and suppresses intrusions of REM-sleep phenomena into waking life. That single deficiency produces the disorder’s full symptom set: excessive daytime sleepiness, cataplexy (sudden muscle weakness triggered by strong emotion), fragmented nighttime sleep, sleep paralysis, and hypnagogic hallucinations. Every therapy approved for NT1 before Orzeyful — sodium oxybate, pitolisant, solriamfetol, and stimulant-class wake-promoting agents — manages some subset of those symptoms without replacing the missing signal itself.

An agonist, not a workaround

Oveporexton works differently: as an OX2R agonist, it directly stimulates the receptor orexin would normally activate, restoring a version of the signaling the disease removes rather than compensating for its absence through sedation or stimulation. In the FirstLight and RadiantLight trials, patients on the 2 mg twice-daily dose showed improved ability to stay awake during the day, a significant reduction in cataplexy episodes, and, notably, meaningful improvement across the disorder’s full spectrum — sleep paralysis and hallucinations included, not just the two symptoms most therapies target. The most common adverse effects reported were insomnia, increased urinary frequency and urgency, and increased saliva production, with a low rate of discontinuation.

Approved does not yet mean available

Orexin receptor agonism is a novel enough central nervous system mechanism that oveporexton has been recommended for scheduling under the Controlled Substances Act, and a Drug Enforcement Administration scheduling decision — expected within roughly 90 days of approval — has to land before any pharmacy can lawfully dispense it. That decoupling is the detail worth tracking separately from the FDA approval date: the practical launch timeline runs on DEA’s Federal Register notice, not Takeda’s label. It is the same two-agency choreography that has slowed other first-in-class CNS drugs to market after FDA clears them, and prescribers who assume an approval letter means a fillable prescription will be wrong for a stretch of the next quarter.